Specially, a study reported that the combination of EZH2 inhibitors and PARP1 inhibitors enhanced lethality in homologous recombination (HR)-proficient and CARM1-high ovarian cancer (50). This evidence concerns the gene EZH2 and ovarian carcinoma.